Filing Details

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

CUSIP No. 81256L104

CUSIP No. 81256L104

 

  

This Schedule 13D is filed on behalf of LMFAO Sponsor, LLC, a Delaware limited liability company (the “Sponsor”), and LMF Funding America, Inc., a Delaware corporation (“LMFA”).

Item 1. Security and Issuer

Securities acquired: Common stock, $0.0001 par value (“Common Stock”)

Issuer: SeaStar Medical Holding Corporation (the “Issuer”)

1200 West Platt Street, Suite 100, Tampa, Florida 33611.

Item 2. Identity and Background

(a) This statement is jointly filed by:

(i) the Sponsor; and

(ii) LMFA, the sole manager of the Sponsor.

All disclosures herein with respect to any Reporting Person are made only by such Reporting Person. Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.

Because LMFA is the sole manager of the Sponsor, LMFA and Sponsor are deemed to have shared voting and investment power over securities owned directly by the Sponsor.

(b) The address of the principal business and principal office of each of the Sponsor and LMFA is 1200 West Platt Street, Suite 100, Tampa, FL 33606.

(c) The Sponsor’s principal business is to act as the Issuer’s sponsor. LMFA’s principal business is bitcoin mining and specialty finance.

(d) None of the Reporting Persons has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

(e) None of the Reporting Persons has, during the last five years, been a party to civil proceeding of a judicial administrative body of competent jurisdiction and, as a result of such proceeding, was, or is subject to, a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or state securities laws or finding any violation with respect to such laws.

(f) The Sponsor is a Delaware limited liability company. LMFA is a Delaware corporation.

Item 3. Source and Amount of Funds or Other Consideration

The aggregate purchase price for the shares of Common Stock currently beneficially owned by the Reporting Persons was $25,000. The aggregate purchase price for the Private Placement Warrants beneficially owned by the Reporting Persons was $5,738,000. The source of these funds was the working capital of the Sponsor and a loan by LMFA to Sponsor.

On October 28, 2022, the Issuer consummated a business combination transaction (the “Business Combination”) pursuant to that certain Agreement and Plan of Merger, dated as of April 21, 2022 (the “Merger Agreement”), by and among LMF Acquisition Opportunities, Inc., a Delaware corporation (“LMAO”), LMF Merger Sub, Inc., a Delaware corporation and direct wholly owned subsidiary of LMAO, and SeaStar Medical, Inc., a Delaware corporation (“SeaStar Medical”). Upon consummation of the Business Combination, each share of Class B Common Stock was automatically converted on a 1-for-1 basis and into Class A Common Stock, and subsequently each share of Class A Common Stock of LMAO was automatically converted on a 1-for-1 basis into Common Stock of the Issuer.

As a result of the foregoing, the shares of Class B Common Stock of LMAO beneficially held by the Reporting Persons were converted into of 2,587,500 shares of Common Stock of the Issuer.

The information set forth in Item 4 and Item 6 of this Schedule 13D is incorporated by reference herein.

Item 4. Purpose of the Transaction

Upon the closing of the Business Combination (i) all shares outstanding of Class B Common Stock of LMAO were converted into shares of Class A Common Stock of LMAO, (ii) all shares of outstanding Class A Common Stock of LMAO were converted into shares of common stock of the Issuer (“Common Stock”) and (iii) LMAO effected a name change to SeaStar Medical Holding Corporation. After such conversions, the Sponsor beneficially owns an aggregate of (i) 2,587,500 shares of Common Stock and (ii) 5,738,000 warrants to purchase shares of Common Stock.

Item 5. Interest in Securities of the Issuer

(a), (b)

The aggregate number and percentage of Common Stock beneficially owned by the Reporting Persons (on the basis of a total of 12,699,668 shares of Common Stock outstanding as of October 28, 2022, as reported by the Issuer in its Current Report on Form 8-K, filed by the Issuer with the SEC on November 4, 2022) are as follows:

(c)

Except for the transactions described in Item 3 and Item 4 of this Schedule 13D, the Reporting Persons have not engaged in any transaction during the past 60 days involving ordinary shares of the Issuer.

(d)

Not applicable.

(e)

Not applicable.

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

Amended and Registration Rights Agreement

On April 21, 2022, LMAO, Sponsor and certain stockholders of the Issuer entered into the Amended and Restated Registration Rights Agreement, which became effective upon the consummation of the Business Combination. The summary of such registration rights agreement contained herein is qualified in its entirety by reference to the full text of such agreement, a copy of which was filed by the Issuer as Exhibit 10.1 to the Form 8-K filed by the Issuer with the SEC on April 26, 2022 (and is incorporated by reference herein as Exhibit 10.1).

Support Agreement.

In connection with the execution of the Merger Agreement, the Sponsor entered into a Sponsor Support Agreement with LMAO and SeaStar Medical pursuant to which the Sponsor agreed, among other things, to vote or cause to be voted (or express consent or dissent in writing, as applicable) all its shares of Common Stock entitled to vote to approve and adopt the Merger Agreement and the Business Combination.

The description of the Support Agreement is qualified in its entirety by reference to the full text of such agreement, a copy of which was filed by the Issuer as Exhibit 10.2 to the Form 8-K filed by the Issuer with the SEC on April 26, 2022 (and is incorporated by reference herein as Exhibit 10.2).

Director Nomination Agreement

At the closing of the Business Combination, the Sponsor and LMAO entered into the Director Nomination Agreement, providing the Sponsor certain director nomination rights, including the right to appoint or nominate for election to the board of directors of the Issuer, as applicable, two individuals, to serve as Class II directors of the Issuer for a certain period following the closing of the Business Combination.

Warrant Agreement

On January 25, 2021, in connection with the IPO, the Issuer entered into a warrant agreement with Continental Stock Transfer & Trust Company, as warrant agent, which governs the terms of the Issuer’s warrants. The summary of such warrant agreement contained herein is qualified in its entirety by reference to the full text of such agreement, a copy of which was filed by the Issuer as Exhibit 4.1 to the Form 8-K filed by the Issuer with the SEC on January 28, 2021 (and is incorporated by reference herein as Exhibit 4.1).

Item 7. Material to be Filed as Exhibits

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.